|
|
|
Full Text: 
|
|
|
|
¿µ³²ÀÇ´ëÇмúÁö Vol.28 No.1 p90-93, June2011
|
|
Case Report
|
|
Torsade de Pointes Induced by Long-Term Oral Amiodarone Therapy |
|
|
|
Jong Ho Nam, Yoon Jung Choi, Min Kyu Kang, Sung Yun Jung, Su Mi Kim, Sang Hee Lee, Dong Gu Shin
|
|
Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea
|
|
|
|
Corresponding Author£ºSang Hee Lee, 317-1 Daemyung-dong, Namgu, Division of Cardiology, Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea
|
|
Tel: (053) 620-3830, Fax: (053) 654-8386
|
|
E-mail : birdizz@hanmail.net
|
|
June 30, 2011
|
|
|
|
Abstract
|
|
|
|
Although amiodarone is generally regarded as safe with a low incidence of associated arrhythmias, torsade de pointes (TdP) has been observed usually in the presence of predisposing factors. We report a case of amiodarone-induced TdP after long-term administration of a low dose of oral amiodarone in the absence of predisposing factors.
|
|
|
|
Key Words: Torsade de pointes, Amiodarone
|
|
|
|
References |
|
|
|
|
|
1. van Opstal JM, Schoenmakers M, Verduyn SC, de Groot SH, Leunissen JD, van Der Hulst FF, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long QT syndrome. Circulation 2001;104: 2722-7.
|
|
|
2. Roden M. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.
|
|
|
3. Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med 2002;112:58-66.
|
|
|
4. Podrid PJ. Amiodarone: reevaluation of an old drug. Ann Intern Med 1995;122:689-700.
|
|
|
5. Roden DM. A practical approach to torsade de Pointes. Clin Cardiol 1997;20:285-90.
|
|
|
6. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: a review with special reference to torsae de pointes tachycardia. Ann Intern Med 1994; 121:529-35.
|
|
|
7. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 2003;82:282-90.
|
|
|
8. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999;99:529-33.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
